<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611962</url>
  </required_header>
  <id_info>
    <org_study_id>EFC_7407</org_study_id>
    <nct_id>NCT00611962</nct_id>
  </id_info>
  <brief_title>Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin</brief_title>
  <official_title>Phase II Study of Combined Oxaliplatin and Paclitaxel for Metastatic Germ Cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of the oxaliplatin-paclitaxel combination i.e. evaluation of tumor&#xD;
      response rate using World Health Organization/Union Internationale Contre le Cancer&#xD;
      (WHO/UICC) and Indianapolis tumor marker (human chorionic gonadotropin [hCG], alpha&#xD;
      fetoprotein [AFP]) criteria in metastatic germ cell cancer patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate efficacy of oxaliplatin-paclitaxel combination using established criteria in metastatic germ cell cancer patients</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety, and toxicity using established criteria,specific neurotoxicity scales, serious adverse events (SAEs) and treatment withdrawals</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Neoplasms, Germ Cell and Embryonal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Paclitaxel</intervention_name>
    <description>Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient&#xD;
Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL.</description>
    <other_name>EloxatinÂ®, Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven germ cell cancer: gonadal (including ovarian) or extragonadal,&#xD;
             seminomatous or non seminomatous, or clinical presentation of a GCT with elevated AFP&#xD;
             level and/or hCG level (&gt; or =to 100 x ULN) when a biopsy was not available&#xD;
&#xD;
          -  Metastatic GCT patients:&#xD;
&#xD;
          -  Progression disease defined as &gt; 10% increase in hCG and/or AFP markers (and/or&#xD;
             documented progressive disease [PD]) during a platinum-based chemotherapy or less than&#xD;
             6 months after the last cycle (in the case of growing non seminomatous tumor, without&#xD;
             increased markers, a histological documentation of malignant tumor was required, to&#xD;
             exclude growing mature teratoma)&#xD;
&#xD;
          -  At least 1 prior line of chemotherapy containing CDDP + etoposide; (prior regimen with&#xD;
             high dose chemotherapy and hematopoietic stem cell support was permitted)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group PS (ECOG PS) grade &lt; or =to 2&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lesion by imaging (CT scan) of &gt; or =to 20 mm&#xD;
             outside an irradiated area OR significantly increased tumor markers &gt; 2 x ULN (on &gt; or&#xD;
             =to 2 consecutive tests, even in the absence of measurable lesions)&#xD;
&#xD;
          -  Age &gt; or =to 18&#xD;
&#xD;
          -  Adequate bone marrow reserve&#xD;
&#xD;
          -  Neutrophil count &gt; or =to 1500/mm3&#xD;
&#xD;
          -  Platelets &gt; or =to 100,000/mm3&#xD;
&#xD;
          -  Renal function:Creatinine &lt; 3 x ULN&#xD;
&#xD;
          -  Liver function:Transaminases &lt; or =to 2.5 x ULN, total bilirubin &lt; 1.5 x ULN (if liver&#xD;
             metastases, transaminases &lt; or =to 5 x ULN)&#xD;
&#xD;
          -  Laboratory values obtained in the week preceding study entry&#xD;
&#xD;
          -  Neurosensory &lt; or =to grade 1 NCI CTC&#xD;
&#xD;
          -  Signed informed consent obtained prior to all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant high-dose steroids (except for antiemetic prophylaxis)&#xD;
&#xD;
          -  Pregnancy, breast-feeding or absence of contraception in sexually active patients&#xD;
&#xD;
          -  Prior treatment with oxaliplatin or taxanes&#xD;
&#xD;
          -  History of second malignancy, except for cured non melanoma skin cancer or excised in&#xD;
             situ cervical carcinoma&#xD;
&#xD;
          -  Symptomatic cerebral and/or leptomeningeal metastasis (irradiated brain metastases not&#xD;
             requiring corticosteroid treatment were allowed)&#xD;
&#xD;
          -  Treatment with another experimental drug or anticancer agent or participation in&#xD;
             another clinical study within 30 days prior to study&#xD;
&#xD;
          -  Other serious illness or uncontrolled infection&#xD;
&#xD;
          -  Psychological, social or geographical situation preventing regular follow-up&#xD;
&#xD;
          -  Primary tumor in brain/central nervous system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Billon</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>January 28, 2008</last_update_submitted>
  <last_update_submitted_qc>January 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Nathalie Billon/Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

